As of May 23, 2025, Mycelx Technologies Corp has a Discounted Cash Flow (DCF) derived fair value of $0.00 per share. With the current market price at $28.50, this represents a potential upside of -5607.8%.
| Key Metrics | Value |
|---|---|
| DCF Fair Value (5-year) | $0.00 |
| DCF Fair Value (10-year) | $0.00 |
| Potential Upside (5-year) | -3071.0% |
| Potential Upside (10-year) | -5607.8% |
| Discount Rate (WACC) | 6.0% - 6.7% |
Revenue is projected to grow from $11 million in 12-2023 to $94 million by 12-2033, representing a compound annual growth rate of approximately 23.9%.
| Fiscal Year | Revenue (USD millions) | Growth |
|---|---|---|
| 12-2023 | 11 | 9% |
| 12-2024 | 4 | -67% |
| 12-2025 | 13 | 246% |
| 12-2026 | 18 | 42% |
| 12-2027 | 24 | 36% |
| 12-2028 | 32 | 32% |
| 12-2029 | 42 | 30% |
| 12-2030 | 52 | 24% |
| 12-2031 | 64 | 25% |
| 12-2032 | 79 | 23% |
| 12-2033 | 94 | 19% |
Net profit margin is expected to improve from -34% in 12-2023 to -12% by 12-2033, driven by operational efficiency and economies of scale.
| Fiscal Year | Net Profit (USD millions) | Profit Margin |
|---|---|---|
| 12-2023 | (4) | -34% |
| 12-2024 | (1) | -24% |
| 12-2025 | (3) | -22% |
| 12-2026 | (3) | -19% |
| 12-2027 | (4) | -17% |
| 12-2028 | (5) | -14% |
| 12-2029 | (6) | -14% |
| 12-2030 | (7) | -13% |
| 12-2031 | (8) | -13% |
| 12-2032 | (10) | -12% |
| 12-2033 | (11) | -12% |
with a 5-year average of $0 million. Projected CapEx is expected to maintain at approximately 5% of revenue.
Depreciation is based on an average useful life of 5 years for capital assets.
| Fiscal Year | D&A (USD millions) |
|---|---|
| 12-2024 | 0 |
| 12-2025 | 0 |
| 12-2026 | 1 |
| 12-2027 | 1 |
| 12-2028 | 1 |
| 12-2029 | 1 |
Net working capital is expected to increase gradually, with projected changes affecting free cash flow.
| Components | Average Days |
|---|---|
| Days Receivables | 86 |
| Days Inventory | 242 |
| Days Payables | 60 |
| Fiscal Year | EBITDA | Tax | CapEx | Change in NWC | FCF |
|---|---|---|---|---|---|
| 6M/2024 | (0) | (0) | 0 | (1) | 1 |
| 2025 | (3) | (0) | 1 | 4 | (7) |
| 2026 | (3) | (0) | 1 | 2 | (5) |
| 2027 | (4) | (1) | 1 | 3 | (8) |
| 2028 | (4) | (1) | 2 | 3 | (8) |
| Valuation Method | Fair Price (USD) | Potential Upside |
|---|---|---|
| 5-Year DCF (Growth) | 0.00 | -3071.0% |
| 10-Year DCF (Growth) | 0.00 | -5607.8% |
| 5-Year DCF (EBITDA) | 0.00 | -100.0% |
| 10-Year DCF (EBITDA) | 0.00 | -100.0% |
Is Mycelx Technologies Corp (MYX.L) a buy or a sell? Mycelx Technologies Corp is definitely a sell. Based on our DCF analysis, Mycelx Technologies Corp (MYX.L) appears to be overvalued with upside potential of -5607.8%. The company's strong projected growth in revenue and profitability, coupled with consistent capital expenditure, supports our positive outlook on its intrinsic value.
Key investment drivers include:
Investors should consider reducing exposure at the current market price of $28.50.